# Dantrolene


Dantrolene is a ryanodine (RYR1) receptor antagonist, which prevents release of Ca^2+^ from the sarcoplasmic reticulum, uncoupling the process of excitation-contraction.

|Property|Dantrolene|
|--|--|
|**Uses**|MH, NMS, ecstasy intoxication, chronic muscle spasticity
|**Presentation**|Vials of orange powder containing 20mg dantrolene and 3g mannitol, reconstituted with 60ml of H~2~O to form an alkaline solution.
|**Dosing**|2.5mg.kg^-1^ IV every 10-15 minutes, up to 10mg.kg^-1^. Once resolved, continue giving 1mg.kg^-1^ every 4-6 hours for 24 hours.
|**Absorption**| IV only, may cause skin necrosis if extravasates.
|**Distribution**|85% protein bound
|**Metabolism**|Hepatic metabolism to active 5-hydroxy-dantrolene
|**Elimination**|Renal of metabolites, t~1/2~Î² of 12 hours
|**Resp**|Respiratory failure due to skeletal muscle weakness
|**CVS**|Volume overload due to large volume given with administration
|**MSK**|Skeletal muscle relaxation
|**Renal**|Diuresis
|**GIT**|Hepatic failure

---

## References

1. Peck TE, Hill SA. Pharmacology for Anaesthesia and Intensive Care. 4th Ed. Cambridge University Press. 2014.\
2. Petkov V. Essential Pharmacology For The ANZCA Primary Examination. Vesselin Petkov. 2012.
3. ANZCA August/September 2011